A Novel Tool Supplying Aeroallergen Information and Allowing for Online, Personalized Symptom Monitoring by Gilles, Stefanie et al.
A Novel Tool Supplying Aeroallergen Information and Allowing for Online, Personalized Symptom Monitoring 
35 
A Novel Tool Supplying Aeroallergen 
Information and Allowing for Online, 
Personalized Symptom Monitoring 
Stefanie Gilles 1, Anna Muzalyova 2, Manuel Glaser 2, Jens Brunner 2, Claudia Traidl-Hoffmann 1,3, 
and Athanasios Damialis 1 
1 Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum 
München, Augsburg, Germany, E-mail: stefanie.gilles@tum.de  
2 Chair of Healthcare Operations and Health Information Management, UNIKA-T, Augsburg University, Augsburg, 
Germany 
3 Christine-Kühne Center for Allergy Research and Education (CK Care), Davos, Switzerland 
Background: Pollen and fungal spores are the most abundant allergen carriers in outdoor air. Pol-
len allergies affect up to 30% of the German population, causing allergic rhinitis, conjunctivitis 
and asthma, whereas information about fungal spore allergies in Germany are scarce. Fungal 
spores have however been associated with the phenomenon of “thunderstorm asthma” in other 
regions of the globe. It is likely that sensitizations to fungal spores and their clinical relevance are 
currently underestimated. Smartphone-based “pollen apps” have been available for several 
years, however, data on the clinical benefit is missing to date. Current “pollen apps”, such as 
PID´s “Pollen” and “Husteblume”, distributed via the Techniker Krankenkasse, consist of a symp-
tom diary and pollen information based on short-term forecasting models. Throughout the main 
pollen season, those apps send the users daily reminders to enter their symptoms. 
 
Aim of study and methods: We aim at the development of a novel smartphone-based allergen 
app that supplies near real-time (3-hourly) pollen and fungal spore information via an automated 
aeroallergen monitor (“PoMo”; Hund, Wetzlar, Germany). Moreover, the app is supposed to al-
low patients to enter their symptoms at the very moment they occur, and to supply personalized 
advice on exposure-relevant behavior and medication to minimize future symptoms. The clinical 
benefit of receiving aeroallergen information will be evaluated in a randomized controlled trial. In 
this trial, all patients will be asked to enter their symptoms in the app during their respective al-
lergen season. One group receives near real-time aeroallergen information, a second group re-
ceives information based on currently used forecasting models and a third group receives no 
aeroallergen information at all. 
 
Conclusion: Apart from possible clinical benefit, the app will be a useful tool for exposome 
research, since it will supply researchers with a high time-resolution of symptom and aeroallergen 
data.  
  
